Skip to content

Methylenedioxymethamphetamine (MDMA) in Psychiatry

Susan Schenk, David Newcombe

Journal of Clinical Psychopharmacology October 10, 2018 DOI: 10.1097/jcp.0000000000000962 via OpenAlex

Summary

AI-generated from the abstract

MDMA (ecstasy) shows some promise as an aid to psychotherapy for posttraumatic stress disorder (PTSD) by increasing prosocial feelings, possibly through oxytocin release and reduced fear conditioning. However, MDMA also carries risks of neurotoxicity and potential for misuse. The article weighs the pros and cons of using MDMA for PTSD, noting that while some evidence suggests it can help patients address underlying trauma, its significant adverse effects raise concerns. Alternative treatments based on MDMA's pharmacology but with fewer side effects are proposed. Further research into the mechanisms behind MDMA's beneficial effects may lead to safer treatment options.

Study at a glance

Characteristics Review Peer reviewed
Topics MDMA
Keywords Hallucinogen Adverse effect Psychology
Citations 53
Key finding MDMA may facilitate recovery from PTSD, but its adverse effects and misuse potential limit its adoption as a pharmacotherapy.

Abstract

Abstract Background For a number of mental health disorders, including posttraumatic stress disorders (PTSD), there are not many available treatment options. Recently, there has been renewed interest in the potential of methylenedioxymethamphetamine (MDMA) to restore function for patients with these disorders. The primary hypothesis is that MDMA, via prosocial effects, increases the ability of patients to address the underlying psychopathology of the disorder. However, the use of MDMA poses potential problems of neurotoxicity, in addition to its own potential for misuse. Methods In this article, the proposed potential of MDMA as an adjunct to psychotherapy for PTSD is evaluated. The rationale for the use of MDMA and the positive results of studies that have administered MDMA in the treatment of PTSD are provided (pros). A description of potential adverse effects of treatment is also presented (cons). An overview of MDMA pharmacology and pharmacokinetics and a description of potential adverse effects of treatments are also presented. Methylenedioxymethamphetamine-produced oxytocin release and decreased expression of fear conditioning as well as one of the MDMA enantiomers (the n R− entaniomer) are suggested as potential mechanisms for the beneficial effects of MDMA in PTSD (suggestions). Results There is some evidence that MDMA facilitates recovery of PTSD. However, the significant adverse effects of MDMA raise concern for its adoption as a pharmacotherapy. Alternative potential treatments with less adverse effects and that are based on the ubiquitous pharmacology of MDMA are presented. Conclusions We suggest that additional research investigating the basis for the putative beneficial effects of MDMA might reveal an effective treatment with fewer adverse effects. Suggestions of alternative treatments based on the behavioral pharmacology and toxicology of MDMA and its enantiomers are presented.

Explore topics

Comments

No comments yet.

Log in to comment